Limited impact of short-term disruptions, growth momentum to continue in FY 23
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
12-week certificate course commences on March 10th 2022
The product will be manufactured at Lupin’s facility in Pithampur, India
The availability of advanced SLED dialysis for critical patients, Plasmapheresis, CRRT machines along with ICCU dialysis complete the centre in every way
Company expects strong organic growth in sales, EBITDA in 2022
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Subscribe To Our Newsletter & Stay Updated